Coherus BioSciences, Inc. Q3 2025 Earnings Recap

Coherus Oncology reported strong Q3 2025 results, demonstrating significant progress in both financial metrics and clinical development, particularly with its promising pipeline of cancer therapies.

Key Takeaways

• Revenue growth, driven by LOQTORZI’s successful market performance in nasopharyngeal cancer, reinforces confidence in achieving future revenue targets.
• The company has improved its balance sheet and reduced expenses, reflecting effective cost management and strategic financial planning.
• Enrollment in clinical trials is progressing well, with promising indications in multiple cancer types, setting the stage for data readouts planned for next year.
• Coherus is focusing on partnerships to enhance clinical development funding and expand the reach of its innovative Treg-depleting therapies, leveraging global rights for key assets.
• Continued advancements in Treg-targeting treatments, especially CHS-114, position Coherus at the forefront of emerging cancer therapies, following significant recognition at industry events.